×
Entero Therapeutics EBIT 2015-2024 | ENTO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Entero Therapeutics ebit from 2015 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Entero Therapeutics EBIT 2015-2024 | ENTO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Entero Therapeutics ebit from 2015 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$119.5B
Regeneron Pharmaceuticals (REGN)
$114.6B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$101.6B
CSL (CSLLY)
$97.4B
GSK (GSK)
$84.8B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.4B
Biogen (BIIB)
$28.2B
BioNTech SE (BNTX)
$28B
Moderna (MRNA)
$24.6B
Illumina (ILMN)
$21.1B
BeiGene (BGNE)
$20.7B
Genmab (GMAB)
$16B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.6B
Incyte (INCY)
$12.5B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$12.4B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.6B
Roivant Sciences (ROIV)
$8.6B
Legend Biotech (LEGN)
$8.5B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$7.7B
Exelixis (EXEL)
$7.5B